Pulmonary Hypertension News Forums › Forums › Research and Development › CTEPH Software Receives “Breakthrough Device” Designation

  • Research & Development

    CTEPH Software Receives “Breakthrough Device” Designation

    Posted by Pulmonary Hypertension News Moderator on December 10, 2018 at 5:18 pm

    The U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to software being developed by Bayer and Merck — known as MSD outside the U.S. and Canada — to help identify chronic thromboembolic pulmonary hypertension (CTEPH). The CTEPH Artificial Intelligence Pattern Recognition Software uses deep learning protocols to improve the analysis of computed tomography pulmonary angiography (CTPA) scans.

    This software is being developed to analyze image findings from cardiac, gas exchange, and pulmonary vessels in combination with the patient’s clinical history. Click here to read more.

    Are you interested in learning more about software and technology related to PH?

    replied 5 years, 5 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .